UK markets closed
  • NIKKEI 225

    -120.20 (-0.42%)

    -275.64 (-1.57%)

    +0.93 (+1.22%)

    -14.70 (-0.84%)
  • DOW

    -457.76 (-1.33%)

    -384.79 (-2.77%)
  • CMC Crypto 200

    -0.96 (-0.25%)
  • ^IXIC

    -180.75 (-1.61%)
  • ^FTAS

    -13.82 (-0.34%)

PCI Biotech: Invitation to Q3 2022 results presentation

PCI Biotech Holding ASA
PCI Biotech Holding ASA

Oslo, Norway, 17 November 2022 - PCI Biotech (OSE: PCIB) invites to an online presentation of the company's Q3 2022 interim report on Wednesday 23 November 2022, 08:30am – 09:30am CET (local time).

The presentation will be held as a live webcast and can be accessed through There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console or through a teleconference facilitated for attendees intending to ask questions verbally during the Q&A session.

The company will be represented by Ronny Skuggedal (CEO/CFO), Anders Høgset (CSO), and Morten Luhr (BD Manager) and the presentation will be held in Norwegian.

PCI Biotech’s Q3 2022 interim report will be released on 23 November 2022 at 07.00am CET. The interim report and presentation will be made available on and on the company's webpage,

For further information, please contact:
Ronny Skuggedal, CEO / CFO
Mobile: +47 9400 5757

About PCI Biotech        
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal release that is used to unlock the true potential of therapeutic modalities.

The fimaVacc programme aims to enhance immunotherapy in cancer, by triggered endosomal release of antigens or nucleic acids encoding antigens, or immunostimulatory factors. In the fimaNAc programme endosomal release is utilised to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For further information, please visit:                
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo            

Forward-looking statements        
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.